Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21582171 | 0.91 | ALOX5 (0.56) | ALOX5MAOBPDGFRBPDGFRAFLT3 | |
| SCHEMBL13744712 | 0.87 | MAOB (0.54) | ALOX5MAOBPDGFRBPDGFRAHDAC8 | |
| SCHEMBL4077230 | 0.84 | MTNR1A (0.47) | ALOX5MAOBPDGFRBPDGFRAABCB1 | |
| SCHEMBL27489226 | 0.80 | MAOB (0.53) | ALOX5MAOBPDGFRBPDGFRAHDAC8 | |
| SCHEMBL19612377 | 0.78 | ALOX5 (0.58) | ALOX5MAOBPDGFRBPDGFRAFLT3 | |
| SCHEMBL19612485 | 0.77 | ALOX5 (0.65) | ALOX5MAOBPDGFRBPDGFRAFLT3 | |
| SCHEMBL19612478 | 0.77 | ALOX5 (0.65) | ALOX5MAOBPDGFRBPDGFRAFLT3 | |
| SCHEMBL1359254 | 0.77 | MAOB (0.50) | ALOX5MAOBPDGFRBPDGFRAFLT3 | |
| SCHEMBL2090976 | 0.75 | MAOB (0.62) | ALOX5MAOBPDGFRBPDGFRAHDAC8 | |
| SCHEMBL18623122 | 0.75 | MAOB (0.62) | ALOX5MAOBPDGFRBPDGFRAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583507-B2 | Direct AMPK activator compounds | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-02-21 | — | — | US | disclosed |
| EP-3968976-A1 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-20220062199-A1 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583507-B2 | Direct AMPK activator compounds | PRKAG2, AK2, PRKAG3 | ALOX5 1849/4885MAOB 3811/4885PDGFRB 3223/4885 |
| US-20220062199-A1 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | PRKAG2, PRKAG1, PRKAG3 | ALOX5 3491/4885MAOB 3790/4885PDGFRB 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.